ALMSNasdaqPharmaceutical PreparationsFiscal year ends December 31

ALUMIS INC.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026

$6.34+0.22 (+3.59%)

Close on Oct 19, 2026

Market cap: $809.56M
P/E (TTM): –
Dividend yield: –

ALUMIS INC. income statement

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31
Revenue	24	–	–
Research & Development	386	266	138
General & Administrative	92	35	20
Operating Expenses	478	301	158
Operating Income	-454	-301	-158
Other Non-Operating Income	202	6.52	3.18
Asset Impairment Charges	0.53	–	–
Gain (Loss) on Sale of Assets	–	-0.01	-0.27
Pretax Income	-252	-294	–
Income Tax Expense	-8.56	0	0
Net Income incl. Noncontrolling Interests	-243	-294	-155
Net Income	-243	-294	-155
Preferred Dividends	–	–	0
EPS (Basic)(per share)	-2.86	-10.38	-72.08
EPS (Diluted)(per share)	-2.86	-10.38	-72.08
Shares Outstanding (Basic, Weighted)(shares)	85	28	2.15
Shares Outstanding (Diluted, Weighted)(shares)	85	28	2.15
EBITDA	-450	-298	-157

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: –
Operating margin: -6204.4%
Net margin: -5933.5%
Return on equity, FY2025: -86.7%

Financial strength

Current ratio: 6.74
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 83.6%

Valuation

P/E ratio: –
Price to sales: 109.43
Price to book: 1.79
Dividend yield: –